Cellectis S.A.
CLLS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.18 | -0.05 | 0.00 | -0.06 |
| FCF Yield | -0.96% | -6.92% | -14.14% | -0.99% |
| EV / EBITDA | 35.20 | -11.31 | -7.83 | 9.06 |
| Quality | ||||
| ROIC | 3.97% | -4.81% | -6.61% | -4.26% |
| Gross Margin | 93.30% | 85.50% | 81.09% | 80.22% |
| Cash Conversion Ratio | -2.67 | 0.43 | 0.95 | -0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 66.25% | 50.84% | 39.54% | 29.62% |
| Free Cash Flow Growth | 74.07% | 39.53% | -879.63% | 72.99% |
| Safety | ||||
| Net Debt / EBITDA | -1.90 | -2.10 | 3.18 | -3.65 |
| Interest Coverage | 3.82 | -4.60 | -7.42 | -6.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -593.96 | -492.26 | -553.07 | -504.86 |